@cherutLmoledet Check out Ishay Ribo's ืืจื ืืขืืฉืื ืืืืื. Following God like a child is exactly the analogy he writes about (following Rashi's commentary). Also Yitzchak's faith in his father during the ืขึฒืงึตืึธื.
@pick1998_2 Yeah I agree, I own a bunch. But they haven't proven the cancer-type-agnostic case yet, so I assume it's only being valued based on the possibility of a small slice of the ovarian cancer market.
@AaronRosenblum5@avidresearch I don't know. It's still February for another week, and they don't have to pre-announce. And they could still pre-announce next week a day in advance.
@HOThomasWPhelps@financebully@aditharun_ I personally couldnโt find any mention of them expecting higher doses to underperform, prior to the actual results. In 2020 they selected 600 mg BID as an expansion dose. I think they only mentioned 200 mg as the optimal dose after they already saw responses in that cohort.
@HOThomasWPhelps@financebully@aditharun_ Without getting into the mechanics of the explanation, did Corvus expect that high doses would underperform? Because when I looked into this, the first time I heard them offer this explanation was after they already collected data showing the 200 mg dose outperformed.
@financebully@HOThomasWPhelps@aditharun_ Well, was the inverse dose response expected before the trial was run? Or was the explanation only discovered after it already happened?
@HOThomasWPhelps@aditharun_ But if this is so clear, why wasnโt 200 mg prespecified as the optimal dose to start with? Isnโt it possible they found the dose did better in the first set of patients, and then crafted a post-hoc explanation to explain random noise?
@Yakovolf While I *want* to agree with you, the left wing radicals took views that offended a majority of Americans. The right wing extremists, on the other hand, seem mostly to be offending us (Jews) and Iโm not sure if the rest of the population actually cares to any real degree.
@monaco_biotech@KingachillesE I did some research on Lynx1, and the founder of the fund did his PhD thesis on nicotinic acetylcholine receptors and the "Lynx1" gene, so I'm assuming he has some personal reason to believe that MK-1167 will work?
@hannibalspeaks If you think it will hit, why sell? I actually bought more based on the research showing that hsCRP is stronger than LDL-C in predicting future CV events for patients on statins. Feels like this could be a blockbuster drug, no?
@MartinShkreli What do you think of $VTYX results? Is reducing hsCRP, IL-6, and Lp(a) evidence it will reduce cardiovascular risk (without affecting obesity directly)?
@MartinShkreli Leaving aside the question of whether this is a game of hot potato, which is always a valid concern when valuation is high, you could argue the value was previously incorrect, perhaps due to excessive pessimism combined with poor management. I assume you're asking about $OPEN...
@MartinShkreli Also, your biotech experience gave you an edge with $ATYR, but I don't think you have an edge with $OPEN. Your argument seems to be valuation-based, but new management can change that. Margins right now aren't great, but execution + scale can override that (see $CVNA).